Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarek Sahmoud

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Breast Cancer Research and Treatment|October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapySara A Hurvitz, Florence Dalenc, Mario Campone, et al.
Clinical Breast Cancer|November 26, 2013
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2Kathleen I Pritchard, Howard A Burris, Yoshinori Ito, et al.
Breast Cancer (Tokyo, Japan)|February 14, 2013
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2Shinzaburo Noguchi, Norikazu Masuda, Hiroji Iwata, et al.
The New England Journal of Medicine|December 14, 2011
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerJosé Baselga, Mario Campone, Martine Piccart, et al.
Cancer|March 19, 2013
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialHoward A Burris, Fabienne Lebrun, Hope S Rugo, et al.
Journal of the National Cancer Institute|February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2Michael Gnant, Jose Baselga, Hope S Rugo, et al.
Lancet (London, England)|November 20, 2012
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2013
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 studyMario Campone, Thomas Bachelot, Michael Gnant, et al.
Current Medical Research and Opinion|August 22, 2013
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapyMario Campone, J Thaddeus Beck, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 studyAtsushi Ohtsu, Jaffer A Ajani, Yu-Xian Bai, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapySara A Hurvitz, Florence Dalenc, Mario Campone, et al.
Clinical Breast Cancer|November 26, 2013
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2Kathleen I Pritchard, Howard A Burris, Yoshinori Ito, et al.
Breast Cancer (Tokyo, Japan)|February 14, 2013
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2Shinzaburo Noguchi, Norikazu Masuda, Hiroji Iwata, et al.
The New England Journal of Medicine|December 14, 2011
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerJosé Baselga, Mario Campone, Martine Piccart, et al.
Cancer|March 19, 2013
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialHoward A Burris, Fabienne Lebrun, Hope S Rugo, et al.
Journal of the National Cancer Institute|February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2Michael Gnant, Jose Baselga, Hope S Rugo, et al.
Lancet (London, England)|November 20, 2012
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2013
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 studyMario Campone, Thomas Bachelot, Michael Gnant, et al.
Current Medical Research and Opinion|August 22, 2013
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapyMario Campone, J Thaddeus Beck, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 studyAtsushi Ohtsu, Jaffer A Ajani, Yu-Xian Bai, et al.
Pageof 3